Opinion|Videos|November 19, 2024
Safety Profiles of Neurokinin-Targeted Therapies for VMS
Key Takeaways
- Elinzanetant showed significant efficacy in reducing VMS frequency and severity, with rapid symptom improvement compared to other treatments.
- The trials highlighted elinzanetant's positive impact on quality of life for women with severe VMS.
Panelists discuss the notable adverse events observed in the OASIS trials with elinzanetant and compare the safety profiles of elinzanetant and fezolinetant with those of traditional treatments for vasomotor symptoms (VMS).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant?
- (FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?
Advertisement
Related to this article
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.
Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.
CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Progress Drives Down US Cancer Death Rates
2
Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care
3
All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected
4
Contributor: Congress Can Bring Mental Health Care to the 21st Century
5